A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Public ClinicalTrials.gov record NCT04485949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.
Study identification
- NCT ID
- NCT04485949
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 99 participants
Conditions and interventions
Conditions
Interventions
- IGV-001 Cell Immunotherapy Combination Product
- Placebo Combination Product
- Standard of Care (SOC): Radiation Therapy Procedure
- SOC: Temozolomide Drug
Combination Product · Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 19, 2023
- Primary completion
- Dec 31, 2026
- Completion
- Jun 30, 2027
- Last update posted
- Jul 8, 2026
2023 – 2027
United States locations
- U.S. sites
- 23
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| John Theurer Cancer Center At Hackensack UMC | Hackensack | New Jersey | 07601 | — |
| Jersey Shore University Medical Center | Neptune City | New Jersey | 07753 | — |
| Northwell Health at North Shore University Hospital | Manhasset | New York | 11030 | — |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Weill Cornell Medicine | New York | New York | 10065 | — |
| Lenox Hill Hospital | New York | New York | 10075 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Westchester Medical Center | Valhalla | New York | 10595 | — |
| University of North Carolina (UNC) - Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| UC Health | Cincinnati | Ohio | 45229 | — |
| The Ohio State University (OSU) Wexner Medical Center | Columbus | Ohio | 43201 | — |
| The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19130 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
| University of Wisconsin - Madison | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04485949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04485949 live on ClinicalTrials.gov.